According to a recent press release, “doc.ai, a blockchain-based artificial intelligence (AI) platform that connects people, data scientists, developers and the healthcare industry to improve patients’ future health outcomes, today announced it is partnering with Anthem, Inc., one of the nation’s leading health benefits companies, to launch a groundbreaking AI data trial on the blockchain. This pioneering 12-month trial, with support from Anthem, will begin in August and explore whether AI can be used to predict when people will experience allergies or allergy patterns. To do so, doc.ai and advisors from Harvard Medical School will develop a framework for using machine learning to identify predictive models for allergies based upon the phenome (e.g., age, height, weight), exposome (e.g., exposure to weather/pollution based on location) and physiome (e.g., physical activity, daily steps) data collected from participating Anthem employees and members of the public. Participants will help accelerate research and benefit from the system’s personalized health insights.”
Gail K. Boudreaux, President and Chief Executive Officer of Anthem, commented, “Anthem is focused on leading our industry in the safe and responsible use of artificial intelligence and emerging technologies to create a better healthcare future for all Americans… We are pleased to partner with doc.ai on this innovative study that can have near-term benefit for our employees and, longer-term, the potential to redefine how we treat disease and manage chronic medical conditions to achieve better personalized health outcomes.”
Read more at PR Newswire.
Photo credit: doc.ai